Nanospectra Biosciences is a private company founded in 2002. Nanospectra has an exclusive license from Rice University to eleven issued US patents related to nanoshells and related commercial uses of these and other nanoparticles. While there are numerous therapeutic, diagnostic, and industrial commercial applications, Nanospectra is focused on the development of AuroLase® Therapy utilizing AuroShell® Particles for the precise, particle-based thermal ablation of solid tumors. 

Nanoshells were developed in the laboratories of Naomi Halas, PhD, at Rice University in the 1990's. In collaboration with Jennifer West, PhD, of Rice University, a series of life science applications were envisioned which led to the formation of Nanospectra. Formal operations were commenced to commercialize these applications. Nanospectra has an open Investigational Device Exemption (IDE) with the U.S. FDA to evaluate the safety and efficacy of AuroLase Therapy for the treatment of refractory or recurrent head and neck cancers. The use of AuroLase Therapy in other cancer types is under development.

We are advised by a group of world-class researchers and healthcare entrepreneurs. In addition, we have been awarded peer-reviewed federal grants and awards exceeding $6 million to develop AuroShell particles for the diagnosis and treatment of cancer and for other diagnostic and commercial applications. Additional funding in excess of $6 million has been raised from angel investors, private investment funds, and the Texas State Emerging Technology Fund.

Company Milestones

2002: Commenced operations, license from Rice University
2003: Successful demonstration of in vivo efficacy in animals
2004: Received Advanced Technology Program award of $2 million; advanced devlopment of manufacturing
2006: Received Texas Emerging Technology Fund award of $1.25 illion; completed cGMP manufacturing facility
2007: Completed animal and laboratory toxicity/safety tests
2008: Received IDE and initiated human clinical trial study for use of AuroLase™ Therapy for refractory/recurrent head and neck cancer
2010 Completed 8 subjects in the head and neck clinical trial
2011 Initiated a pilot study of AuroLase™ Therapy for primary prostate cancer (Mexico)
2012 Treated final subject in prostate cancer pilot study (Mexico); trail completed Q1 2013
2012 Received IDE and initiated human clinical trial study for use of AuroLase™ Therapy for primary and/or metastatic lung tumors










For More Information

For questions or additional information regarding Investor Relations, please
contact Glenn Goodrich at GGoodrich@Nanospectra.com or 713-842-2720 ext 225.